Raloxifene and endothelial function in healthy postmenopausal women

American Journal of Obstetrics and Gynecology

Volumn 188, Issue 2, 2003, Pages 304-309

  Sarrel, Philip M ^a,b   Nawaz, Haq ^a,b   Chan, Wendy ^b   Fuchs, Melissa ^a   Katz, David L ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale Griffin Prevention Research Center   (United States)

Author keywords

Endothelial response; Healthy postmenopausal women; Raloxifene

Indexed keywords

PLACEBO; RALOXIFENE;

ADULT; AREA UNDER THE CURVE; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTHRALGIA; ARTICLE; BLOOD VESSEL REACTIVITY; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; EDEMA; FEMALE; FEVER; HEADACHE; HEART PROTECTION; HOARSENESS; HOT FLUSH; HUMAN; HYPEREMIA; INSOMNIA; LASER DOPPLER FLOWMETRY; LEG CRAMP; MENOPAUSAL SYNDROME; MYALGIA; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; STIMULUS RESPONSE; TREATMENT PLANNING; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN;

EID: 0037330374     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2003.28     Document Type: Article

References (25)

1. Vogel R. Coronary risk factor, endothelial function, and atherosclerosis: a review. Clin Cardiol 1997;20:426-32.
2. Herrington D, Braden G, Downes T, Williams J. Estrogen modulates coronary vasomotor responses in postmenopausal women with early atherosclerosis. Am J Cardiol 1994;73:951-7.
3. Collins P, Rosano GM, Sarrel PM, Ullrich L, Adamopoulos S, Beale CM, et al. 17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995;92:24-30.
4. Gilligan D, Badar D, Panza J, Quyyumi A, Cannon RO III. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994;90:786-91.
5. ++ mobilization. Circ Res 1997;81:1680-7.
6. Simoncini T, Genazzani A. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 2000;85:2966-9.
7. Figtree G, Lu Y, Webb C, Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 1999;100:1095-101.
8. Zoma W, Baker R, Clark K. Coronary and uterine vascular resonses to raloxifene in the sheep. Am J Obstet Gynecol 2000;182:521-8.
9. Herrington DM, Pusser BE, Riley WA, Thuren TY, Brosnihan KB, Brinton EA, et al. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 2000;20:1606-12.
10. Saitta A, Altavilla D, Cucinotta D, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001;21:1512-9.
11. Cerquetani E, Mercuro G, Fini M, et al. Hormone replacement therapy but not raloxifene improves endothelial function in postmenopausal women with increased cardiovascular risk. Proceedings of the 12th Annual Meeting of the North American Menopause Society; 2001 Oct 4-6; New Orleans, La. New Orleans: The Society; 2001.
12. Sorenson K, Celermajer D, Spiegelhalter K, et al. Non-invasive measurement of human endothelium-dependent arterial responses: accuracy and reproducibility. Br Heart J 1995;74:247-53.
13. Sarrel P, Lindsay D, Rosano G, Poole-Wilson P. Angina and normal coronary arteries in women: gynecologic findings. Am J Obstet Gynecol 1992;167:467-71.
14. Anderson T, Uehata A, Gerhard M, Meredith I, Knab S. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26:1235-41.
15. Williams S, Cusco J, Roddy M, Johnstone M, Creager M. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996;27:567-74.
16. Celermajer D, Adams M, Clarkson P, et al. Passive smoking and impaired endothelium-dependent arterial dilation in healthy young adults. N Engl J Med 1996;334:150-4.
17. Vogel R, Corretti M, Plotnick G. The postprandial effect of components of the Mediterranean diet on endothelial function. J Am Coll Cardiol 2000;36:1455-60.
18. Marchesi S, Lupattelli G, Schillaci G, et al. Impaired flow-mediated vasoactivity during post-prandial phase in young healthy men. Atherosclerosis 2000;153:397-402.
19. Knottnerus J, Bouter L. The ethics of sample size: two-sided testing and one-sided thinking. J Clin Epidemiol 2001;54:109-10.
20. Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen? Circulation 1995;92:5-8.
21. Clarkson T, Anthony M, Jerome C. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998;83:721-6.
22. Barrett-Connor E, Cox D, Anderson P. The potential of SERMs for reducing the risk of coronary heart disease. Trends Endocrinol Metab 1999; 10:320-325.
23. valk de Roo G, Stehower C, Meijer P, et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 1999;19:2993-3000.
24. Walsh B, Kuller L, Wild R, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-51.
25. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.